Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Parkinson’s Disease

  • Chapter
Drug Studies in the Elderly

  • 50 Accesses

Abstract

Drugs used to treat Parkinson’s disease fall into six main categories: (1) levodopa; (2) extracerebral decarboxylase inhibitors; (3) artificial dopamine agonists; (4) monoamine oxidase inhibitors; (5) anticholinergic agents; and (6) amantadine. Levodopa is the cornerstone of Parkinsonism disease treatment. The other five drug classes are useful supplements or occasional alternatives to levodopa.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Evans MA, Triggs EJ, Broe GA, et al: Systemic availability of orally administered L-Dopa in the elderly parkinsonian patient. Eur J Clin Pharmacol 1980; 17: 215–221.

    Article  PubMed  CAS  Google Scholar 

  2. Evans MA, Broe GA, Triggs EJ, et al: Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 1981; 31: 1288–1294.

    PubMed  CAS  Google Scholar 

  3. Wurtman RJ, Hirsch MJ, Growdon JH: Lecithin consumption raises serum free choline levels. Lancet 1977; 2: 68.

    Article  PubMed  CAS  Google Scholar 

  4. Nutt JG, Woodward WR, Hammerstad JP, et al: The “on-off” phenomenon in Parkinson’s disease. N Engl J Med 1984; 310: 483–488.

    Article  PubMed  CAS  Google Scholar 

  5. Nutt JG, Fellman JH: Pharmacokinetics of levodopa. Clin Neuropharnuacol 1984; 7: 35–49.

    Article  CAS  Google Scholar 

  6. Ward CD, Trombley IK, Caine DB, et al: L-dopa decarboxylation in chronically treated patients. Neurology 1984; 34: 198–201.

    PubMed  CAS  Google Scholar 

  7. Schwab RS, England AC, Poskanzer DC et al: Amantadine in the treatment of Parkinson’s disease. JAMA 1969; 208: 1168–1170.

    CAS  Google Scholar 

  8. Cotzias GC, Papavasiliou MD, Tolosa ES, et al: Treatment of Parkinson’s disease with Aporphines. N Engl J Med 1976; 294: 567–572.

    Article  PubMed  CAS  Google Scholar 

  9. Schran HF, Bhuta SI, Schwarz HJ, et al: The pharmacokinetics of bromocriptine in man, in Goldstein M, Caine DB, Lieberman A, Thorner ML (eds): Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatrie Aspects. New York, Raven Press, 1980, pp 125–139.

    Google Scholar 

  10. Burns RS, Caine DB: Disposition of dopaminergic ergot compounds following oral administration, in Caine DB, Horowski R, McDonald RJ, et al (eds): Lisuride and Other Dopamine Agonists. New York, Raven Press, 1983, pp 153–160.

    Google Scholar 

  11. Humpel M, Nieuweboer B, Wendt H: Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: Effects on plasma prolactin level. Eur] Clin Pharmacol 1981; 20: 47–51.

    Article  CAS  Google Scholar 

  12. Glover V, Sandler M, Owen F, et al: Dopamine is a monoamine oxidase B substrate in man. Nature 1977; 265: 80–81.

    Article  PubMed  CAS  Google Scholar 

  13. Schachter M, Marsden CD, Parkes D, et al: Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiatry 1980; 43: 1016–1021.

    Article  PubMed  CAS  Google Scholar 

  14. Chiba K, Trevor A, Castagnoli N: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984; 120: 574–578.

    Article  PubMed  CAS  Google Scholar 

  15. Lees AJ, Kohout LJ, Shaw KM, et al: Deprenyl in Parkinson’s disease. Lancet 1977; 2: 791–795.

    Article  PubMed  CAS  Google Scholar 

  16. Rinne UK, Siirtola T, Sonninen V: t.-Deprenyl treatment of on-off phenomena in Parkinson’s disease. J Neural Transmission 1978; 43: 253–262.

    Article  CAS  Google Scholar 

  17. Eisler T, Teravainen H, Nelson R, et al: Deprenyl in Parkinson’s disease. Neurology 1981; 31: 19–23.

    PubMed  CAS  Google Scholar 

  18. Duvoisin RC: Cholinergic—anticholinergic antagonism in Parkinsonism. Arch Neurol 1967; 17: 124–136.

    Article  PubMed  CAS  Google Scholar 

  19. Farnebo L, Fuxe K, Hamberger B, et al: Effect of some antiparkinsonian drugs on catecholamine neurons. J Pharm Pharmacol 1970; 22: 733–737.

    Article  PubMed  CAS  Google Scholar 

  20. Quinn NP: Anti-parkinsonian drugs today. Drugs 1984; 28: 236–262.

    Article  PubMed  CAS  Google Scholar 

  21. Burke RE, Fahn S: Pharmacokinetics of trihexyphenidyl after acute and chronic administration. Ann Neural 1982; 12: 94.

    Google Scholar 

  22. Whitehouse PJ, Price DL, Clarke AW, et al: Alzheimer’s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122–126.

    Article  PubMed  CAS  Google Scholar 

  23. Pacifici GM, Nadini M, Ferari P: Effect of amantadine on drug-induced parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmacol 1976; 3: 883–889.

    PubMed  CAS  Google Scholar 

  24. Montanari C, Ferrari P, Bavazzano A: Urinary excretion of amantadine by the elderly. Eur J Clin Pharmacol 1975; 8: 349–351.

    Article  PubMed  CAS  Google Scholar 

  25. Kurland LT, Kurtzke JF, Goldberg ID: Epidemiology of Neurologic and Sense Organ Disorders. Cambridge, MA, Harvard University Press, 1973, pp 436.

    Google Scholar 

  26. Fluckiger E, Briner U, Enz A, et al: Dopaminergic ergot compounds: an overview, in DB Calne et al (eds): Lisuride and Other Dopamine Agonists. New York, Raven Press, 1983, pp 1–9.

    Google Scholar 

  27. Larsen TA, Newman R, Le Witt P, et al: Severity of Parkinson’s disease and the dosage of bromocriptine. Neurology 1984; 34: 795–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurology, Department of Medicine, Health Sciences Centre Hospital, University of British Columbia, Vancouver, British Columbia, Canada, V6T 1W5

    Donald B. Calne & Arto Laihinen

Authors
  1. Donald B. Calne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arto Laihinen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Geriatrics Cedars-Sinai Medical Center, University of California-Los Angeles School of Medicine, 90048, Los Angeles, California, USA

    Neal R. Cutler M.D. (Director) (Director)

  2. Clinical Pharmacokinetics Research Laboratory Pharmacy Department Clinical Center, National Institutes of Health, 20892, Bethesda, Maryland, USA

    Prem K. Narang Ph.D. (Supervisor) (Supervisor)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Plenum Publishing Corporation

About this chapter

Cite this chapter

Calne, D.B., Laihinen, A. (1986). Pharmacological Treatment of Parkinson’s Disease. In: Cutler, N.R., Narang, P.K. (eds) Drug Studies in the Elderly. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1253-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-1253-6_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-1255-0

  • Online ISBN: 978-1-4684-1253-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation